Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

Background Hyponatremia (serum sodium concentration, Methods In two multicenter, randomized, double-blind, placebo-controlled trials, the efficacy of tolvaptan was evaluated in patients with euvolemic or hypervolemic hyponatremia. Patients were randomly assigned to oral placebo (223 patients) or ora... View More